433 related articles for article (PubMed ID: 30190720)
1. Recent Developments in Recombinant Protein-Based Dengue Vaccines.
Tripathi NK; Shrivastava A
Front Immunol; 2018; 9():1919. PubMed ID: 30190720
[TBL] [Abstract][Full Text] [Related]
2. Dengue vaccine: an update on recombinant subunit strategies.
Martin J; Hermida L
Acta Virol; 2016 Mar; 60(1):3-14. PubMed ID: 26982462
[TBL] [Abstract][Full Text] [Related]
3. Targets and strategies for vaccine development against dengue viruses.
Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
[TBL] [Abstract][Full Text] [Related]
4. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
5. Working towards dengue as a vaccine-preventable disease: challenges and opportunities.
Shrivastava A; Tripathi NK; Dash PK; Parida M
Expert Opin Biol Ther; 2017 Oct; 17(10):1193-1199. PubMed ID: 28707486
[TBL] [Abstract][Full Text] [Related]
6. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
7. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
[TBL] [Abstract][Full Text] [Related]
8. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
Coller BA; Clements DE; Bett AJ; Sagar SL; Ter Meulen JH
Vaccine; 2011 Sep; 29(42):7267-75. PubMed ID: 21777637
[TBL] [Abstract][Full Text] [Related]
9. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
10. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Martinez DR; Metz SW; Baric RS
Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
[TBL] [Abstract][Full Text] [Related]
11. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
Sun J; Li M; Wang Y; Hao P; Jin X
Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
[TBL] [Abstract][Full Text] [Related]
12. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
13. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
14. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
15. Antibody recognition of the dengue virus proteome and implications for development of vaccines.
Fernandez S; Cisney ED; Tikhonov AP; Schweitzer B; Putnak RJ; Simmons M; Ulrich RG
Clin Vaccine Immunol; 2011 Apr; 18(4):523-32. PubMed ID: 21270280
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.
Chiang CY; Pan CH; Chen MY; Hsieh CH; Tsai JP; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
Sci Rep; 2016 Jul; 6():30648. PubMed ID: 27470096
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial.
Durbin AP; Pierce KK; Kirkpatrick BD; Grier P; Sabundayo BP; He H; Sausser M; Russell AF; Martin J; Hyatt D; Cook M; Sachs JR; Lee AW; Wang L; Coller BA; Whitehead SS
Am J Trop Med Hyg; 2020 Aug; 103(2):855-863. PubMed ID: 32394880
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
[TBL] [Abstract][Full Text] [Related]
19. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
20. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
